<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076595</url>
  </required_header>
  <id_info>
    <org_study_id>15098</org_study_id>
    <secondary_id>BF0910FR</secondary_id>
    <nct_id>NCT01076595</nct_id>
  </id_info>
  <brief_title>Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period</brief_title>
  <acronym>SEPLUS</acronym>
  <official_title>Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the SEPLUS study is to evaluate the patients characteristics associated with
      adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in
      the BetaPlus program
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The adherence to treatment (rate of patients continuing with Betaferon速 regimen after 24 months)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance to Betaferon according physician (rate of patients with compliance rater &gt; 94,5%)</measure>
    <time_frame>6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment (rate of patients continuing with the Betaferon速 regimen at 6 and 12 months)</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with prematurely study discontinuation</measure>
    <time_frame>0-6 months, 6-12 months, 12-18 months, 18-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's autonomy with regard to the Betaferon速 injections (Number of injections realized by the patient alone/total number of injections)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Betaferon injections (rate and number of injections)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Quality of Life (Mean total score of FAMS [Functional Assessment of Multiple Sclerosis])</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue (mean total score of FSS [Fatigue Severity scale])</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of clinical Condition( annual rate of Relapses)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with change of in EDSS (Expanded Disability Status Scale) &lt; 1 between M0 and end of the study</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with change in EDSS&lt; 1 and no relapse between M0 and M24</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">73</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b (Betaseron, BAY86-5046)</intervention_name>
    <description>Betaferon 250 microgram</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      n.a
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;/= 18 years old

          -  Outpatient with a confirmed diagnosis of Recurrent-Remittent multiple sclerosis or
             patients at high risk of developing multiple sclerosis after a first demyelinating
             clinical event

          -  Patient who initiated Betaferon as described by SmPC less than 2 months ago. The
             decision of physician is clearly separated from the decision to include the patient in
             the study

          -  Treatment na誰ve patients before the initiation of Betaferon

          -  OR Patients having interrupted Betaferon for more than 6 months before to start again

          -  OR Patients receiving a disease modifying drug (DMD) other than Betaferon

          -  Patient with EDSS score &lt; 4

          -  Patients approved and signed an inform consent and approved the collect of their data

        Exclusion Criteria:

          -  Contraindications and warning of the respective Summary of Product Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results provided by Bayer</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>BetaPlus program</keyword>
  <keyword>Recurrent/remittent multiple sclerosis patients</keyword>
  <keyword>Adherence to treatment regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

